Nathan Yumibe

Discovery of 1-(4-Fluorophenyl)-(3<i>R</i>)-[3-(4-fluorophenyl)-(3<i>S</i>)- hydroxypropyl]-(4<i>S</i>)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235):  A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption

Stuart B. Rosenblum, Tram Huynh, Adriano Afonso et al. · Journal of Medicinal Chemistry · 1998 · 352 citations

Serum Total Cholesterol, Pharmaceutical Science, Pharmacotherapy +18

In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH48461

Margaret van Heek, Constance F. France, Douglas S. Compton et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 305 citations

Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine

Nathan Yumibe, Keith Huie, Kwang-Jong Chen et al. · Biochemical Pharmacology · 1996 · 104 citations

Nonsedating Antihistamine Loratadine, Biochemistry, Medicine +9

Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes

Mark D. Leibowitz, Robert Ardecky, Marcus F. Boehm et al. · Endocrinology · 2005 · 69 citations · Full text

Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor

Yvonne Y. Yip, Frantz Victor, Jason Lamar et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 65 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +9